Compare HOV & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOV | ACRS |
|---|---|---|
| Founded | 1959 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.0M | 868.5M |
| IPO Year | 1994 | 2015 |
| Metric | HOV | ACRS |
|---|---|---|
| Price | $122.55 | $6.16 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $97.00 | $10.20 |
| AVG Volume (30 Days) | 106.2K | ★ 1.6M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $2,978,581,000.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.96 | $4.24 |
| P/E Ratio | $76.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $91.52 | $1.74 |
| 52 Week High | $162.06 | $6.60 |
| Indicator | HOV | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 48.86 |
| Support Level | $97.80 | $5.64 |
| Resistance Level | $127.03 | $6.56 |
| Average True Range (ATR) | 7.22 | 0.31 |
| MACD | -1.28 | -0.06 |
| Stochastic Oscillator | 35.83 | 26.23 |
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.